Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
Companies
» Company Monitoring Page for Novartis
Company Monitoring Page for Novartis
latest headlines for company on cafepharma
Novartis updates on Sandoz finances ahead of spin-off
Pharmaphorum
Tue, 09/5/23 - 11:18 am
Tags:
Novartis
,
Sandoz
,
spinoffs
,
generics
,
biosimilars
Novartis hits back at Entresto selection on Medicare list
Pharmaphorum
Wed, 08/30/23 - 09:59 am
Tags:
Novartis
,
Entresto
,
drug pricing
,
Medicare
Novartis: Leqvio Provides Low-density Lipoprotein Cholesterol Reduction Beyond 6 Years Of Treatment
RTT News
Mon, 08/28/23 - 12:05 pm
Tags:
Novartis
,
Leqvio
,
LDL cholesterol
,
clinical trials
Novartis Abandons Xoma-Partnered Antibody for Pancreatic Cancer
BioSpace
Mon, 08/28/23 - 11:39 am
Tags:
Novartis
,
Xoma
,
NIS793
,
pancreatic cancer
FDA Decisions 2023: Sandoz, Gilead Sciences and More
BioSpace
Fri, 08/25/23 - 11:31 am
Tags:
FDA
,
Sandoz
,
Novartis
,
Gilead Sciences
,
Pfizer
,
Neurocrine
,
Regeneron
,
Ipsen
,
Revance Therapeutics
,
Delcath Systems
,
Janssen
,
Galera Therapeutics
,
Biogen
,
Roche
,
Mesoblast
,
Taiho Oncology
The Biopharma Patent Cliff: 9 Drugs Losing Exclusivity by the End of 2023
BioSpace
Wed, 08/23/23 - 11:11 am
Tags:
patent cliff
,
patents
,
Takeda
,
Vyvanse
,
Pfizer
,
Eraxis
,
JNJ
,
Stelara
,
Merck
,
Isentress
,
Eiger Pharmaceuticals
,
Zokinvy
,
Astellas
,
Myrbetriq
,
Novartis
,
Entresto
,
Amgen
,
Otzela
Novartis to lay off another 100-plus employees at US HQ as global restructuring rolls on
Fierce Pharma
Tue, 08/22/23 - 11:38 pm
Tags:
Novartis
,
layoffs
,
New Jersey
Zacks Industry Outlook Highlights Eli Lilly, J&J, Novo Nordisk, Novartis and AstraZeneca
Yahoo/Zacks.com
Tue, 08/22/23 - 09:58 am
Tags:
earnings
,
Eli Lilly
,
JNJ
,
Novo Nordisk
,
Novartis
,
AstraZeneca
Novartis cites strong sales growth for $15B Sandoz spin-off as board vote unanimously for separation
Biopharma Reporter
Mon, 08/21/23 - 06:50 pm
Tags:
Novartis
,
Sandoz
,
spinoff
,
biosimilars
,
generics
Novartis floats share distribution scheme as it plots Sandoz spinoff for Oct. 4
Fierce Pharma
Fri, 08/18/23 - 11:29 am
Tags:
Novartis
,
Sandoz
,
spinoffs
,
generics
,
biosimilars
Sandoz plans to enter the Eylea biosimilar race
Clinical Trials Arena
Tue, 08/15/23 - 10:03 am
Tags:
Sandoz
,
generics
,
biosimilars
,
Eylea
,
Novartis
,
wet age-related macular degeneration
Spinal Muscular Atrophy: Four trials to watch over the next 12 months
Clinical Trials Arena
Fri, 08/11/23 - 11:39 am
Tags:
clinical trials
,
spinal muscular atrophy
,
Scholar Rock
,
apitegromab
,
Novartis
,
Zolgensma
,
Spinraza
,
clenbuterol
Novartis prepares for FDA submission for its chronic hives treatment
Clinical Trials Arena
Wed, 08/9/23 - 10:15 am
Tags:
Novartis
,
remibrutinib
,
chronic hives
,
FDA
Novartis sickle cell drug’s approval formally revoked by EU regulators
BioPharma Dive
Sun, 08/6/23 - 09:27 pm
Tags:
Novartis
,
Adakveo
,
sickle cell disease
,
Europe
,
EMA
Biosimilar makers split strategies in bid to take on top-selling Humira
BioPharma Dive
Thu, 07/27/23 - 10:25 am
Tags:
biosimilars
,
Humira
,
AbbVie
,
rebates
,
drug pricing
,
Amgen
,
Celltrion
,
Novartis
,
Boehringer Ingelheim
,
Biocon
,
Fresenius
,
Sandoz
,
Organon
,
Coherus
Scratching the surface of the urticaria pipeline
EP Vantage
Thu, 07/20/23 - 10:00 am
Tags:
chronic urticaria
,
Sanofi
,
Dupixent
,
Regeneron
,
Novartis
,
Roche
,
Xolair
,
Allakos
,
AstraZeneca
,
Celldex Therapeutics
Novartis raises drug sales forecast, plans new stock buybacks
BioPharma Dive
Tue, 07/18/23 - 10:23 pm
Tags:
Novartis
Novartis axes secretive obesity program after high-risk, high-reward bet fails
Fierce Biotech
Tue, 07/18/23 - 11:41 am
Tags:
Novartis
,
obesity
,
pancreatic cancer
Novartis buys a preclinical biotech and its RNA drug technology
BioPharma Dive
Mon, 07/17/23 - 07:07 pm
Tags:
Novartis
,
DTxPharma
,
siRNA
,
M&A
Novartis retreats from TIGIT, handing $300M candidate back to BeiGene
Fierce Biotech
Tue, 07/11/23 - 10:22 am
Tags:
Novartis
,
anti-TIGIT
,
BeiGene
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »
last 30 twitter posts
current feelings about your job
job rating
*
1 - I hate my job
2
3
4
5
6
7 - I love my job
Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
please tell us why
*
your industry
*
your job title (optional)
your company
*
published
N/A
published
not published
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
An earthquake would most likely shake a: idea, building, breeze
*
Fill in the blank.